Skip to content

Management of breastfeeding in the incidence of hospitalization for hyperbilirubinemia in newborns.

Effectiveness of breastfeeding management on weight gain and bilirubin levels in newborns: a randomized clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3kdnvsg
Enrollment
96
Registered
2026-04-22
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newborn

Interventions

This is a randomized controlled clinical trial with two parallel arms and no blinding (open-label). The study will include a total of 94 mother–newborn dyads, with 47 participants allocated to the Int
assessment of breastfeeding technique through direct observation of feeding
practical correction of positioning and latch, including proper newborn alignment, adequate areola grasp, and correct positioning of lips and chin
health education and counseling using clear communication, active listening, empathy, and positive reinforcement, including guidance on on-demand breastfeeding, the importance of colostrum, skin-to-sk
and identification and management of breastfeeding-

Sponsors

Universidade Federal do Piauí
Lead Sponsor
Universidade Federal do Piauí
Collaborator

Eligibility

Age
24 Hours to 48 Hours

Inclusion criteria

Inclusion criteria: Newborns of both sexes; aged between 24 and 48 hours of life; with gestational age between 37 weeks and 41 weeks and 6 days; and birth weight between 2,500 g and 3,999 g.

Exclusion criteria

Exclusion criteria: Newborns with congenital malformations perceptible on physical examination or reported by the mother; jaundice in the first 24 hours of life; ABO and/or Rh incompatibility; family history of a sibling treated with phototherapy for neonatal jaundice; Asian descent; or the presence of cephalohematoma or ecchymoses, since these conditions constitute risk factors for significant hyperbilirubinemia in neonates with a gestational age greater than 35 weeks.

Design outcomes

Primary

MeasureTime frame
It is expected to evaluate the reduction of bilirubin levels in newborns; verified through standardized clinical assessment (Kramer scale); the outcome will be considered as the decrease in bilirubin levels and/or the absence of need for therapeutic interventions, such as phototherapy or exchange transfusion, according to established clinical guidelines.

Secondary

MeasureTime frame
It is expected to evaluate newborn weight gain; verified through weight measurement using a calibrated scale at defined time points (at birth, between 24 and 48 hours, and on the 7th day of life); the outcome will be considered as the variation in weight in grams between the evaluated time points, including recovery of birth weight or adequate weight gain according to neonatal parameters.

Countries

BR

Contacts

Public ContactMaria Bezerra

Universidade Federal do Piauí

mariaaugusta@ufpi.edu.br+55-89-35222716

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: May 1, 2026